
X-In8 Biologicals Corporation Profile last edited on: 1/15/14
CAGE: 5LM96
UEI: F135FGK8SD46
Business Identifier: therapies to fight inflammation and other tissue damage Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 04
County: Orange
Congr. District: 04
County: Orange
Public Profile
Biotechnology company X-in8 Biologicals Corp., a spinoff from the laboratories at the University of North Carolina at Chapel Hill. X-in8 is developing therapies that can fight inflammation and other tissue damage as blood flow is restored after the blood supply has been restricted for a period of time, such as after an organ transplant. The damage that can occur is called ischemia-reperfusion injury, or IRI. Prncipals of the firm are working on a way to keep naturally occurring proteins from contributing to IRI. Egan said the compounds he is developing could reduce tissue damage after transplants. The technology could also be developed for heart surgery as well as heart attack and stroke applications.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2011 | 1 | NIH | $291,826 | |
Project Title: Tlr4 Inhibition To Reduce Cerebral Ischemia Reperfusion Injury | ||||
2010 | 1 | NIH | $321,746 | |
Project Title: The Effect of Tlr4 Inhibition on Lung Transplant Ischemia-Reperfusion Injury |
Key People / Management
Thomas Egan -- President
Perry A Genova -- President & CEO
Lori Ann Holle
Perry A Genova -- President & CEO
Lori Ann Holle
Company News
There are no news available.